Know Cancer

forgot password

A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension.

Phase 2
18 Years
Open (Enrolling)
Metastatic Malignant Melanoma, Unresectable Malignant Melanoma

Thank you

Trial Information

A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension.

Inclusion Criteria:

- Previously treated or untreated, histologically confirmed, metastatic and
unresectable melanoma with progressive disease

- Both BRAF wild type patients as well as BRAF mutated patients are allowed. For BRAF
mutated patients, BRAF targeting agents should be considered in first line if
otherwise indicated and no contraindications exist.

- WHO performance status 0-1

- Age >18 years,

- Known BRAF mutation

- Able to undergo outpatient treatment

- Patients must have clinically and/or radiographically documented measurable disease
according to RECIST.

- All radiology studies must be performed within 28 days prior to registration (35 days
if negative).

- At least 4 weeks since adjuvant interferon alpha

- At least 4 weeks since 1st line treatment in case of metastasis

- Major surgical procedure or significant traumatic injury > 28 days prior to study
treatment start. Biopsy or fine needle aspiration > 2 days prior to study treatment
start. Central venous line placement must be inserted at least 2 days prior to
treatment start.

- Only patients with irradiated and asymptomatic brain metastases and off dexamethasone
are allowed.

- Hematology: absolute granulocytes > 1.0 x 109/L

- Platelets > 100 x 109/L

- Bilirubin < 1.5 x upper normal limit

- Serum creatinine < 1.5 x upper normal limits

- LDH < 1.5 x upper normal limit

- INR < 1.5

- Absence of any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the

- Before patient registration/randomization, written informed consent must be given
according to national and local regulations.

Exclusion Criteria:

- No previous DTIC

- No previous anti-VEGF targeted therapies

- No pregnant or lactating patients can be included

- No clinical evidence of coagulopathy

- No unstable angina pectoris

- No AV-block II or III without pacemaker

- No severe congestive heart failure

- No untreated phaeochromocytoma

- No severe bradycardia

- No severe hypotension

- No severe impairment of peripheral arterial circulation

- No uncontrolled cardiac arrhythmia

- No severe asthma or COPD

- No uncontrolled diabetes mellitus

- No Angioneurotic edema

- No severe Aortic valve stenosis

- No severe hypertrophic cardiomyopathy

- No severe renal dysfunction

- No patients on beta blockers/ ACE inhibitors by inclusion unable/unwilling to
discontinue beta blockers/ ACE inhibitors and convert to other classes of
antihypertensive drugs

- No full-dose oral coumarin-derived anticoagulants (INR>1.5) or heparin, thrombolytic
agents, or chronic, daily treatment with aspirin (>325 mg/day).

- No uncontrolled hypertension

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression free survival

Outcome Description:

Participants will be followed for the duration of the treatment and as long as they do not progress, an expected average of 6 months

Outcome Time Frame:

Average of 6 months

Safety Issue:


Principal Investigator

Oddbjorn Straume, MD PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Oncology, Haukeland University Hospital, Bergen, Norway


Norway: Norwegian Medicines Agency

Study ID:




Start Date:

January 2013

Completion Date:

June 2016

Related Keywords:

  • Metastatic Malignant Melanoma
  • Unresectable Malignant Melanoma
  • Melanoma